272 related articles for article (PubMed ID: 27002306)
1. Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.
Wang W; Liu Y; Zhao Z; Xie C; Xu Y; Hu Y; Quan H; Lou L
Cancer Sci; 2016 Jun; 107(6):782-90. PubMed ID: 27002306
[TBL] [Abstract][Full Text] [Related]
2. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Bhatia S; Diedrich D; Frieg B; Ahlert H; Stein S; Bopp B; Lang F; Zang T; Kröger T; Ernst T; Kögler G; Krieg A; Lüdeke S; Kunkel H; Rodrigues Moita AJ; Kassack MU; Marquardt V; Opitz FV; Oldenburg M; Remke M; Babor F; Grez M; Hochhaus A; Borkhardt A; Groth G; Nagel-Steger L; Jose J; Kurz T; Gohlke H; Hansen FK; Hauer J
Blood; 2018 Jul; 132(3):307-320. PubMed ID: 29724897
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
4. Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines.
Alves R; Santos D; Jorge J; Gonçalves AC; Catarino S; Girão H; Melo JB; Sarmento-Ribeiro AB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770876
[TBL] [Abstract][Full Text] [Related]
5. Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Huang H; Weng H; Dong B; Zhao P; Zhou H; Qu L
Sci Rep; 2017 Jan; 7():41525. PubMed ID: 28128329
[TBL] [Abstract][Full Text] [Related]
6. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
7. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
9. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
[TBL] [Abstract][Full Text] [Related]
11. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
[TBL] [Abstract][Full Text] [Related]
12. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
13. Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins.
Chen WY; Chang FR; Huang ZY; Chen JH; Wu YC; Wu CC
J Biol Chem; 2008 Jun; 283(25):17184-93. PubMed ID: 18442981
[TBL] [Abstract][Full Text] [Related]
14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
15. Bag1 directly routes immature BCR-ABL for proteasomal degradation.
Tsukahara F; Maru Y
Blood; 2010 Nov; 116(18):3582-92. PubMed ID: 20675402
[TBL] [Abstract][Full Text] [Related]
16. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
17. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
18. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin.
Demidenko ZN; An WG; Lee JT; Romanova LY; McCubrey JA; Blagosklonny MV
Cancer Biol Ther; 2005 Apr; 4(4):484-90. PubMed ID: 15846067
[TBL] [Abstract][Full Text] [Related]
19. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
